Leucocyte- and platelet-rich fibrin as a rescue therapy for small-to-medium-sized complex wounds of the lower extremities

Kadri Ozer 1* and Ozlem Colak 2

Abstract

Background: Generally, advanced wound care resources are applied for complex wounds that pose a challenge to the medical and nursing teams. In this report, the use of leukocyte- and platelet-rich fibrin (L-PRF) is emphasized for complex wounds as an alternative, simple, inexpensive, time-saving process that does not require hospitalization and has a healing potential over that of bare soft tissue, including bone, tendon, and ligaments. The aim of this study is to extend the use of L-PRF in small-to-moderate-sized complex wounds of lower extremities in which L-PRF maintains the sensitive structures viable.

Methods: Between January 2016 and December 2017, 17 small-to-moderate-sized complex wounds of lower extremities treated with L-PRF were recruited from the plastic and reconstructive surgery clinic in Aydin State Hospital, Turkey. The treatment was administered twice per week in the outpatient clinic. Depending on the size and extension of the complex wound, two to five blood samples were collected into 8.5 ml dry, glass vacuum tubes with no anticoagulant, and samples were immediately centrifuged at 1630×g for 5 min to obtain L-PRF. Complete healing was defined as the day of complete wound epithelialization.

Results: The median values of the initial wound size and wound duration were 12 cm² (interquartile range, 6 to 23 cm²) and 8 months before first admission (interquartile range, 4 to 18 months), respectively. All wounds showed significant improvements after L-PRF therapy and full closure after a median of 18 months, with an interquartile range of 11 to 34 months of L-PRF applications. There were recurrences of wounds during the first 6 months after therapy. No adverse events were observed.

Conclusions: Our results add to the growing evidence that L-PRF treatments protect and maintain bare soft tissue structures viable, facilitate the formation of granulation tissue and epithelization, and remarkably reduce the need for additional soft tissue surgeries in small-to-medium-sized complex wounds.

Keywords: Leukocyte- and platelet-rich fibrin, Complex wound, Bare bone, Bare tendon

Background

Non-healing ulcers (unresponsive to initial therapy or persisting despite appropriate care and standard treatment) represent a substantial financial burden on the health care system [1]. “Advanced wound care methods” are considered when standard treatments have failed. In developed countries, it is estimated that 1 to 2% of the population will experience a chronic wound during their lifetime [2].

According to a new report, the global market for advanced wound care products will reach US$ 16.0 billion by 2022 [3]. The most common encountered chronic wounds are ulcers of the lower extremities, which usually last, on average, 12 to 13 months and therefore remain a major workload problem for clinicians [4]. Moreover, the biggest repercussions of such wounds are the decrease in quality of life and productivity of patients. In working patients, leg ulcers are correlated with loss of time from work, loss of jobs, and adverse effects on finances [2].

Chronic wounds are classically defined as wounds that have failed to proceed through an orderly and timely

* Correspondence: kadriozer@hotmail.com; kadri.ozer@saglik.gov.tr
1Aydin State Hospital, Plastic, Reconstructive and Aesthetic Surgery Clinic, 09100 Aydin, Turkey
Full list of author information is available at the end of the article
reparative process to produce anatomic and functional integrity over a period of 3 months [5]. Although this definition has frequently been used, the term “chronic wound” only means that more time is needed to heal the wound. Hence, it could be argued that this term is not a good for characterizing the complexity of the problem [6]. Consequently, it would be better to use the term “complex wounds” rather than “chronic wounds” to describe well-known, difficult wounds that challenge medical and nursing teams regardless of whether they are acute or chronic [6].

Management of complex wounds has undergone major developments over the past decade, and the interest in the field of wound care has led to advancements of the use of tissue engineering and biological products. Recently, platelet-based products have gained significance and are currently some of the most commonly used biological products for wound healing. Although the use of platelet derivatives for the treatment of skin wounds has a five-decade history with various names [7], the first-known accepted description of the regenerative use of platelets was provided by Marx in 1998 as platelet-rich plasma (PRP) [8]. PRP was described as an autologous source of growth factors, such as platelet-derived growth factor, and the obtained growth factor-beta was transformed by sequestering and concentrating platelets via gradient density centrifugation [8]. After the working definition was provided by Marx et al. [8], platelet-based bioactive treatments gained in popularity in many areas, including dentistry, oral and maxillofacial surgery, dermatology, and cosmetic surgery. Described as an easily obtained, fast, effective, relatively cheap, and safe product, PRP has been the subject of increased clinical interest in the market [9]. Despite its widespread use, one of its reported drawbacks is the use of anticoagulation factors, which may cause a delay in normal wound-healing processes [10]. Additionally, ready-to-use commercially available disposable PRP preparations and separation kits could cost US$ 175–1150 per kit [11]. Therefore, the high costs and the need for specialized equipment to prepare PRP could critically reduce the use of autologous platelets in clinical practice [11]. Akhundov et al. commented that more simplified methods that do not require ad hoc and costly equipment would help to accumulate clinical data and introduce the method in a routine manner in clinical practice [11]. Therefore, it was necessary to develop manual methods for the preparation of low-cost PRP or to create different biological methods. Given these limitations, manual PRP techniques have evolved, and studies focused on developing a second-generation platelet concentrate. Consequently, a platelet concentrate lacking coagulation factors, which was later termed platelet-rich fibrin (PRF), was developed based on its anticipated properties in tissue regeneration and wound healing [10].

An autologous, solid, fibrin biomaterial was first introduced in 2000s. Leukocyte- and platelet-rich fibrin (L-PRF) has a very specific three-dimensional architecture (thick and dense polymerized fibrin strands), cell content, and distribution (97% of the platelets and > 50% of the leukocytes from the initial blood harvest) [12]. The growth factor content of L-PRF was logically expected to be much higher that of PRP as most platelets are activated in L-PRF clots [13]. An intact PRF membrane slowly releases 273.4 ± 15.3 ng transforming growth factor-ß1 (TGF-ß1), 6071 ± 773 pg vascular endothelial growth factor (VEGF) and 50.3 ± 6.3 ng platelet-derived growth factor-AB (PDGF-AB) over 7 days, which represent large amounts of these growth factors [13, 14].

In recent years, the interest in biological products, primarily in autologous platelet-rich preparations, has increased. The rationale of this study is related to the use of L-PRF concentrations, which is a relatively recent development that differs from other preparations given its potential for healing and neoangiogenesis [15]. In addition, the unique three-dimensional structure of L-PRF contains a known capacity of platelets, leukocytes, and growth factors that persist in the application site, providing superior prolonged action compared with other preparations [15]. In this report, the use of L-PRF on complex leg wounds is and presented as an alternative, simple, and low-cost method. The technique is fast and does not require hospitalization, leading to less time lost from work and good healing potential given that granulation tissue forms on bare bones, tendons, and ligaments in small-to-medium-sized wounds. The aim of this study is to extend the use of L-PRF in small-to-moderate-sized complex wounds, in which L-PRF maintains the sensitive structures viable and protects them from necrosis.

**Methods**

**Study design and patient selection**

A retrospective review was performed to evaluate the therapeutic effects of L-PRF on patients with complex wounds. Between January 2016 and December 2017, 17 small-to-moderate-sized complex wounds of lower extremities treated with L-PRF were recruited from plastic and reconstructive surgery clinic in Aydin State Hospital, Turkey. This institution is a station hospital where patients are sent from the surrounding counties, and the plastic surgery department is the only department that treats complex wounds. All the protocols used in this study were conducted according to the ethical guidelines of the 1975 Declaration of Helsinki and international regulations as reflected in the approval of the study by the Ethics Committee of Ankara Training and Research Hospital, Ankara, Turkey (0040/0408). Notably, informed consent was obtained from each patient. All cases reported in this study were treated in the...
outpatient clinic without the need for hospitalization or an operating room. Patients’ age and gender and the initial wound size, wound type, comorbidities, wound etiology, injured soft tissue structures, number of treatments, and duration of wound were identified and reviewed from their medical records.

The L-PRF treatment was applied twice per week until the wound was completely epithelialized. No extra specialized wound care was performed. Additionally, a topical antibiotic ointment (5 mg/g neomycin, 500 IU/g bacitracin) was occasionally applied as a prophylactic treatment when dressings were performed exclusively in the presence of an erythematous appearance around the wound. The primary endpoint was healing on consecutive days. Complete healing was defined as the day of complete wound epithelialization. Wound information was either collected by the medical personnel assessing the wounds or obtained from photographs of the wounds. In our clinical practice, wound measurements are made of the greatest length and width, and those measurements are multiplied to obtain the area of the initial wound size.

**Inclusion and exclusion criteria**

The following inclusion criteria were used in this study: (a) patients over 18 years of age; (b) patients with well-known, difficult wounds that challenge medical and nursing teams regardless of whether they are acute or chronic; (c) patients with a chronic wound in need of another treatment that has not been healed by specialized wound care; (d) patients without any extra specialized wound care material other than L-PRF applications; and (e) patients with a minimum follow-up period of 6 months. The exclusion criteria were as follows: (a) patients with anemia or thrombocytopenia, (b) patients with suboptimal wound care before first admission, (c) patients with necrotic wounds because it was believed that platelets would be unable to penetrate the wound bed [16], and (d) patients with a disease and/or medication affecting platelet function and structure.

**L-PRF preparation and application**

Two to five blood samples (depending on the size and extension of the defect to be filled) were collected in 8.5 ml dry, glass vacuum tubes with no anticoagulant and were immediately centrifuged at 1630×g for 5 min (see Additional file 1: Video S1). To prevent initiation of coagulation cascades before centrifugation and to allow natural transformation of the fibrin matrix during centrifugation, this step was performed as soon as blood was collected in the tubes. After centrifugation, three layers were observed. The basal layer consisted of red blood cells (most dense), the top layer consisted of non-cellular plasma (least dense), and the middle layer consisted of the L-PRF coagulate (medium density). Using sterile forceps, L-PRF was removed from the tube and stripped from the adjacent red blood cell layer (Fig. 1). With absorption of L-PRF serum into a gauze pad, a membrane rich in fibrin from the matrix that exhibited high resistance was obtained. During each visit, after mild irrigation and mild debridement of the wound, L-PRF treatment was applied and the wound was covered with a few thick pieces of gauze. All the procedures, including opening the wound, irrigation, debridement, preparation and application of L-PRF, and re-dressing, took approximately 10 to 15 min, on average.

**Statistical analysis**

Data were analyzed using SPSS 15.0 software (SPSS, Chicago, IL, USA). Data are presented as the median and interquartile ranges. Spearman’s rank correlation

---

*Fig. 1 Leukocyte- and platelet-rich fibrin is observed in the middle layer and is stripped from the adjacent red blood layer with a sterile forceps before application*
### Table 1
Demographic data and clinical characteristics of the patients involved in the study. PRF: platelet-rich fibrin

| Patient | Gender | Age (years) | Comorbidities                                                                 | Affected site                              | Initial wound size – length × width (cm²) | Duration of wound at first admission (months) | Number of PRF treatments | Wound healing time (weeks) |
|---------|--------|-------------|-------------------------------------------------------------------------------|--------------------------------------------|------------------------------------------|---------------------------------------------|--------------------------|--------------------------|
| 1       | Male   | 72          | Diabetes mellitus, hypertension, peripheral arterial disease                   | Left foot back                             | 9 × 7                                    | 8                                           | 36                       | 18                       |
| 2       | Male   | 76          | Diabetes mellitus, hypertension, chronic venous insufficiency                 | Left distal lower leg lateral              | 5 × 7                                    | 18                                          | 48                       | 24                       |
| 3       | Male   | 65          | Diabetes mellitus, peripheral arterial disease                               | Right middle lower leg anterior            | 6 × 2                                    | 4                                           | 8                        | 4                        |
| 4       | Male   | 18          | Distal flap necrosis after posttraumatic flap surgeries                       | Right middle lower leg anterior            | 3 × 2                                    | 2.5                                         | 52                       | 26                       |
| 5       | Male   | 43          | Non-healing gunshot injury                                                    | Right middle lower leg posterior           | 5 × 3                                    | 2                                           | 18                       | 9                        |
| 6       | Female | 58          | Diabetes mellitus, hypertension, peripheral arterial disease                   | Left distal lower leg medial              | 4 × 2                                    | 9                                           | 12                       | 6                        |
| 7       | Female | 63          | Diabetes mellitus, hypertension, peripheral arterial disease                   | Right foot medial plantar                | 2 × 2                                    | 7                                           | 12                       | 6                        |
| 8       | Male   | 56          | Arteriovenous malformation, hypertension, uncontrolled psoriasis, chronic venous insufficiency | Right foot heel                           | 5 × 5                                    | 240                                         | 60                       | 30                       |
| 9       | Female | 60          | Diabetes mellitus, peripheral arterial disease                               | Right distal lower leg medial             | 2 × 1                                    | 8                                           | 8                        | 4                        |
| 10      | Female | 65          | Diabetes mellitus, hypertension, arterial stenosis                            | Left distal foot lateral                  | 6 × 3                                    | 6                                           | 20                       | 10                       |
| 11      | Male   | 48          | Chronic obstructive pulmonary disease, hypertension, necrosis after tumor resection | Left foot dorsomedial                     | 3 × 2                                    | 4                                           | 12                       | 6                        |
| 12      | Male   | 65          | Diabetes mellitus, peripheral arterial disease                               | Left middle lower leg medial              | 4 × 3                                    | 6                                           | 10                       | 5                        |
| 13      | Female | 58          | Peripheral arterial disease, cardiac valvular disease                         | Right foot dorsolateral                   | 3 × 3                                    | 12                                          | 12                       | 6                        |
| 14      | Male   | 64          | Chronic obstructive pulmonary disease, hypertension                           | Right proximal leg anteromedial           | 5 × 5                                    | 20                                          | 32                       | 16                       |
| 15      | Male   | 58          | Peripheral arterial disease, chronic venous insufficiency                     | Right distal lower leg medial             | 5 × 3                                    | 18                                          | 24                       | 12                       |
| 16      | Male   | 77          | Diabetes mellitus, hypertension, chronic venous insufficiency, posttraumatic non-healing wound | Left calcaneal medial                     | 2 × 2                                    | 3                                           | 8                        | 4                        |
| 17      | Female | 62          | Diabetes mellitus, chronic venous insufficiency                              | Left metatarsophalangeal joint lateral     | 7 × 3                                    | 36                                          | 26                       | 13                       |
was used to determine the association between the initial
wound size, duration of the wound, and number of
L-PRF applications. Statistically significant was consid-
ered as \( p < 0.05 \).

Results

Demographic data and clinical characteristics of patients

L-PRF-treated wounds showed hastened healing with
early wound contraction. Out of 17 patients, 11 patients
(65%) were male and 6 (35%) were female, with a mean
age of 59 years (ranging from 18 to 77 years) (Table 1).
There were three acute wounds with a median duration
of 2.5 months before first admission (interquartile range,
2 to 3 months) that occurred after trauma and 14
chronic wounds with a median duration of 8.5 months
before first admission (interquartile range, 6 to 18.5
months) (Table 1). The median initial wound size at first
admission was 12 cm\(^2\) (interquartile range, 6 to 23 cm\(^2\))
(Table 1).

The median number of L-PRF applications was 18,
with an interquartile range of 11 to 34 months (Table 1).
The correlation between the initial wound size and the
number of L-PRF applications was statistically significant
\( (r_s = 0.699, p = 0.002) \). However, no correlation was
found between the duration of the wound and the num-
ber of L-PRF applications \( (r_s = 0.445, p = 0.73) \).
There was a statistically significant positive correlation between
the initial wound size and the duration of the wound \( (r_s =\)
0.524, \( p = 0.031) \).

Some of the cases are presented in Figs. 2, 3, 4, 5, 6,
and 7. There was no wound recurrence for at least
6 months after therapy. Notably, adverse events related
to therapy were not observed. A topical antibiotic oint-
ment (5 mg/g neomycin sulfate, 500 IU/g bacitracin) was
occasionally used in two patients. The ointment was ap-
plied around the L-PRF application when dressings were
placed as a prophylactic treatment due to the erythema-
tous appearance of the wound. However, no infection
was observed during the treatment period. Final photo-
graphs of one patient were not found in the archives,
and he did not answer our phone calls for a control visit
and photographing (Case No: 8). No other complications
and/or events were noted in the study.

Case samples

Figure 2 shows a 72-year-old fit and independent man
with a history of diabetes mellitus complicated by a soft
tissue infection on his left foot extending to the lower
leg. After hospitalization and intravenous antibiotic ther-
apy in the infectious disease unit, 80% of the total dorsal
area of the foot was affected by necrosis. The patient
underwent surgical debridement and transposition flap
surgeries with skin grafting of the donor sites. Due to
distal flap necrosis, the bare tendons of the foot were ex-
posed after sharp debridement (Fig. 2a). We performed
L-PRF treatment twice per week (Fig. 2b). During each
visit, the bare tendons were viable and white in color,
unlike those in other commercial dressing materials
(Fig. 2c–e). A completely healed foot was obtained with-
out any observed complications (Fig. 2f). Similar results
were observed in a 76-year-old male with multiple co-
morbidities who presented with a one-and-a-half-year
history of a chronic venous ulcer on his left lower leg
(Fig. 3a–e). An interesting case of a non-healed wound
secondary to trauma in a 65-year-old male who had an
advanced peripheral arterial disease with diabetic dermo-
pathy was also observed, and the wound was successfully
healed after 8 L-PRF applications (Fig. 4a–d). An ex-
ample of an acute complex wound sample was a healthy
young male who sustained a right tibial fracture from a
motorbike injury, requiring surgical open reduction and
internal fixation by a plate and screws. Additionally, he

---

**Fig. 2** A 72-year-old man presented with necrosis of 80% of the total dorsal area of his foot after a soft tissue infection due to uncontrolled diabetes mellitus. **a** Bare tendons of the dorsal foot defect after sharp debridement due to distal flap necrosis, and **b** application of leukocyte- and platelet-rich fibrin (L-PRF) over the defect. **c** After five applications of L-PRF, a small granulation tissue started to appear with viable exposed tendons. **d** Six weeks after the first application, the wound contracted and the formed granulation tissue almost covered the whole bare tendon at the medial side. **e** Eight weeks after the first application, the wound contracted and greater than 50% of the initial wound was epithelialized. **f** After 18 weeks of L-PRF application, a completely healed complex wound was obtained with no complications.
underwent consecutive flap surgeries, including a hemi-
soleus muscle flap with skin grafting and a transpos-
tional fasciocutaneous flap due to recurrent distal
necrosis of the flaps (Fig. 5a). After unsuccessful surger-
ies, the patient did not prefer to undergo another sur-
gery. L-PRF treatment was subsequently applied to the
patient. The wound was observed to contract after appli-
cation (Fig. 5b). Approximately 6 months later, the defect
was uneventfully closed (Fig. 5c).

Discussion
Bioactive substances and their effects are hotly debated
in the field of regenerative medicine. The main area of
research seems to focus on the biology of platelets and
leukocytes in wound-healing processes. Unfortunately,
many studies mainly focus on growth factors. The fibrin
architecture and the leukocyte content of these products
are also often neglected [17]. The presence of leukocytes
has a strong impact on the biology of these products not
only given their immune and antibacterial properties but
also their major key roles in the wound-healing process
and local factor regulation [17].

The beneficial effect of L-PRF membranes in the heal-
ing of complex leg wounds can be explained by their
high concentration of platelets and leukocytes together
with the long-term release of growth factors specific to
the L-PRF matrix [7]. The presence of a fibrin matrix
enhances the delivery of growth factors over the wound
area. Unlike PRP, L-PRF does not dissolve quickly; it dis-
solves over hours after application. Hence, L-PRF sus-
tains a very significant slow release of key growth factors
for days, which means that PRF stimulates its environ-
ment for a significant amount of time during the
wound-healing process [14]. We hypothesize that the
slow release of key growth factors during the first week
may explain the positive results of PRF that we observed
in our patients: “maintaining the viability of bare and
vulnerable tissues such as tendon, bone, and/or liga-
ments.” In an in vitro study that included endothelial cell
cultures and chick embryo chorioallantoic membrane
assays, PRF preparations were somewhat more potent in
angiogenesis than PRP preparations [18]. Leukocytes are among the main motivators of bone and soft tissue regeneration and contribute to the release of the angiogenic and lymphogenic factors responsible for cellular crosstalk in the tissue regeneration process [19]. Accordingly, without leukocytes, sophisticated cell–cell communication for tissue regeneration is not possible [19]. The increased presence of these cells potentially influences the differentiation of macrophages, which are key cells derived from the myeloid lineage and are implicated in growth factor secretion during wound healing, including TGF-beta, PDGF, and VEGF [10, 20, 21].

On the other hand, fibroblasts are the most influential cells in the production of collagen and other extracellular matrix components. Fibroblasts within chronic wounds have been shown to arrest the cell cycle [22]. For the initiation of wound-healing processes, it is important to induce the activation of the arrested cell cycles of fibroblasts within chronic wounds. Fibroblast proliferation is precisely regulated by cell cycle regulatory proteins, which are composed of two protein classes, cyclins and their kinase partners cyclin-dependent kinases (Cdks). Fibroblasts are strongly reactive to growth factors, including fibroblast growth factor-beta, epidermal growth factor, and PDGF. Notably, the expression of cyclins and cyclin-dependent kinase proteins increases in response to high concentrations of platelet-based suspensions [22]. These suspensions induced the upregulation of type I collagen as well as increased cell migration, proliferation rates, and expression of G1 cell cycle regulatory proteins, such as cyclin A, Cdk2, and cyclin E, in human skin fibroblasts [22].

The main controversy regarding L-PRF involves whether the presence of leukocytes has a beneficial or detrimental effect. Leukocytes produce catabolic cytokines that may impair tissue healing. On the other hand, some authors believe that leukocytes provide antimicrobial effects and natural protection against allergic responses [23, 24]. Although L-PRP and L-PRF are rich in leukocytes, increased total amounts of IL-1β were observed in blood clots with L-PRF and L-PRF due to the partial loss of leukocytes during L-PRP and L-PRF.

Fig. 5 A healthy young male presented with a complex wound, including bare bone and peripherally unqualified skin and soft tissue, after tibial fracture surgeries to treat a motorbike injury. a After unsuccessful surgical operations, the patient did not prefer to undergo another surgery. b Leukocyte- and platelet-rich fibrin treatment was subsequently applied to the patient, and the wound gradually started to contract. c Approximately 6 months later, the defect was uneventfully closed.

Fig. 6 A 43-year-old-male presented with a non-healing gunshot injury. a Granulation tissue of the fasciectomy area after treatment with a vacuum-assisted closure system. In this healing period, the non-healed area was observed. b Leukocyte- and platelet-rich fibrin (L-PRF) application on the complex wound area of the gunshot injury. c Wound healing after six applications of L-PRF, d and wound healing after 12 applications of L-PRF. e The complex wound was uneventfully healed after 18 applications of L-PRF.
preparations [25]. The interleukin (IL)-1β concentration was previously found to be positively correlated with neutrophils and monocytes in L-PRP concentrates [26]. One study reported that more than half of leukocytes were trapped in PRF membranes; small lymphocytes were mainly collected but were not correlated with inflammation [12].

Leukocytes are also involved in the communication between precursor cells and mesenchymal cells with regard to bone formation [19]. The strongest induction of mesenchymal stem cell migration was observed in response to L-PRF, which may suggest the complexity of growth factors and cell interactions in cellular processes during tissue healing [25]. It should be noted that a pure growth factor or cytokine could have an inconsistent effect compared with the cocktail of factors present in wound healing. Ultimately, it can be hypothesized that L-PRF may provide a continuous and prolonged growth factor and cytokine system that involves a cascade of complex, orderly, and elaborate events with an acceptable environment for tissue injuries.

Limitations
An acknowledged limitation of this study is the lack of a control group for L-PRF applications. A prospective study including patients undergoing L-PRF treatment compared with either another treatment or saline could be possible. However, it could be argued that comparing a treatment modality with a no treatment response control group would be unwise and unethical. Notably, L-PRF applications were performed in all of our patients with non-healed complex wounds despite their current wound care. On the other hand, while L-PRF may be considered helpful in wound healing and furthermore may essentially bypass some of the limitations of commercial single-growth factors, it is not the “holy grail” of wound healing. Other limitations of this study include the small sample size of the study and the single-center nature of the study.

Conclusions
In our study, we used L-PRF to treat complex wounds in lower extremities. Tendon, and/or bone exposure commonly occurs in wounds of lower extremities. In addition, it could be challenging to form healthy granulation tissue by simple dressings in such exposed tissues while maintaining the viability of vulnerable tissues. For such wounds, an advanced therapy is recommended in the literature for those who do not respond to standard treatments within 4 weeks. Additionally, if a patient has any additional morbidities or problems, which can make surgery impossible and difficult, the clinician should seek alternative options other than surgery in small-to-medium-sized complex wounds. Due to the idealistic concept of primum non nocere, the clinician may experience a contradiction between doing no harm and doing better. Therefore, in these circumstances, L-PRF could represent a good alternative for small-to-medium-sized complex wounds because it can be prepared in a user-friendly manner with autologous, inexpensive, effective, and protective dressing materials and does not require any hospitalization. In conclusion, our results contribute to the growing evidence regarding the treatment modality of L-PRF. L-PRF protects and maintains the exposed tissues viable to facilitate the formation of granulation tissue, increase epithelization, and reduce the need for additional soft tissue surgery in small-to-medium-sized complex wounds.

Additional file

Additional file 1: Video S1. Video demonstrating how to manually harvest and apply leukocyte- and platelet-rich fibrin. (MP4 200367 kb)

Abbreviations
Cdks: Cyclin-dependent kinases; L-PRF: Leukocyte- and platelet-rich fibrin; PDGF-AB: Platelet-derived growth factor-AB; PRP: Platelet-rich plasma; TGF-β1: Transforming growth factor-β1; VEGF: Vascular endothelial growth factor

Acknowledgements
The authors would like to acknowledge our nurse Emel Yetkin for her help with patient follow-up.

Funding
The authors confirm that they received no funding or support for this work and had no financial interests to declare.

Availability of data and materials
The datasets used and/or analyzed in the current study are available from the corresponding author upon reasonable request.
Authors’ contributions
KO performed the follow up of the patients. KO and OC wrote the manuscript and performed all of the revisions. OC performed the literature review and was responsible for the editorial duties of the manuscript. All of the authors were actively involved in the planning and enactment of the study and also assisted with the preparation of the submitted article. The authors have read and agreed to the final submitted version of the paper and bear responsibility for it.

Ethics approval and consent to participate
Ethical approval was obtained before the study by the ethics committee of Ankara Training and Research Hospital.

Consent for publication
Written informed consent was obtained from the patients for the publication of this article and any accompanying images.

Competing interests
The authors declare that they have no competing interests.

Author details
1Aydın State Hospital, Plastic, Reconstructive and Aesthetic Surgery Clinic, 09100 Aydın, Turkey. 2Istanbul Okmeydani Training and Research Hospital, Plastic, Reconstructive and Aesthetic Surgery Clinic, 34384 Istanbul, Turkey.

Received: 29 October 2018 Accepted: 20 March 2019

Published online: 06 May 2019

References
1. Greer N, Foman NA, MacDonald R, Dorrian J, Fitzgerald P, Rutks I, et al. Advanced wound care therapies for nonhealing diabetic, venous, and arterial ulcers: a systematic review. Ann Intern Med. 2013;159:532–42.
2. Sen CK, Gordillo GM, Roy S, Kirsner R, Lambert L, Hunt TK, et al. Human skin wounds: a major and snowballing threat to public health and the economy. Wound Repair Regen. 2000;8:763–71.
3. The global advanced wound care market (MCP-6191). 2016. Available from: http://www.strategyr.com/MarketResearch/ViewInfoGraphNew.asp?code=MCP-6191.
4. Frykberg RG, Banks J. Challenges in the treatment of chronic wounds. Adv Wound Care. 2015;4:560–82.
5. Wedin F, Tenenhaus M, Schaller H-E, Rennekampff H-O. Evidence-based management strategies for treatment of chronic wounds. Eplasty. 2009;9:e19.
6. Ferreira MC, Tuma P, Carvalho VF, Kamamoto F. Complex wounds. Clinics (Sao Paulo). 2006;61:571–8.
7. Pinto NR, Ubbilla M, Zamora Y, Del Rio V, Doah Ehrenfest DM, Quirynen M. Leucocyte- and platelet-rich fibrin (L-PRF) as a regenerative medicine strategy for the treatment of refractory leg ulcers: a prospective cohort study. Platelets Taylor & Francis. 2017;00:1.
8. Man RE, Carlson ER, Eichstaedt RM, Schimmerle SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998;85:638–46.
9. Magalón J, Bausset O, Serancine N, Giraudo L, Aboudou H, Veran J, et al. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 2014;30:625–38.
10. Miron RJ, Fujikawa-Kobayashi M, Bishara M, Zhang Y, Hernandez M, Fibrin CJP-R, Healing STW. A systematic review. Tissue Eng Part B Rev. 2016;23:0233.
11. Akhundov K, Pietramaggiore G, Waselle L, Daniche C, Gueirid S, Scaletta C, et al. Development of a cost-effective method for platelet-rich plasma (PRP) preparation for topical wound healing. Ann Burns Fire Disasters. 2012;25:207–13.
12. Dohan Ehrenfest DM, Del Corso M, Doss A, Mouly J, Charrier JB. Three-dimensional architecture and cell composition of a Choukroun’s platelet-rich fibrin clot and membrane. J Periodontol. 2010;81:571–8.
13. Dohan Ehrenfest DM, Del Corso M, Inchingolo F, Sammartino G, Charrier JB. Platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) in human cell cultures: growth factor release and contradictory results. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology. 2010;110:418–21.
14. Dohan Ehrenfest DM, de Peppo GM, Doglioli P, Sammartino G. Slow release of growth factors and thrombospordin-1 in Choukroun’s platelet-rich fibrin (PRF): a gold standard to achieve for all surgical platelet concentrates technologies. Growth Factors. 2009;27:63–9.
15. Chignon-Sicard B, Georgiou CA, Fontas E, David S, Dumas P, Thi I, et al. Efficacy of leukocyte- and platelet-rich fibrin in wound healing: a randomized controlled clinical trial. Plast Reconstr Surg. 2012;130:819e–29e.
16. Steenvoorde P, van Droom LP, Naves C, Olsman J. Use of autologous platelet-rich fibrin on hard-to-heal wounds. J Wound Care. 2008;17:60–3.
17. Bielecki T, Doan Ehrenfest DM, Everts PA, Wiczkowski A. The role of leukocytes from L-PRP/L-PRF in wound healing and immune defense: new perspectives. Curr Pharm Biotechnol. 2012;13:1153–62.
18. Kobayashi M, Kawase T, Okuda K, Wollf LF, Yoshie H. In vitro immunological and biological evaluations of the angiogenic potential of platelet-rich fibrin preparations: a standardized comparison with PRP preparations. Int J Implant Dent. 2015;1:11.
19. Choukroun J, Ghaani S. Reduction of relative centrifugation force within injectable platelet-rich fibrin (PRF) concentrates advances patients’ own inflammatory cells, platelets and growth factors: the first introduction to the low speed centrifugation concept. Eur J Trauma Emerg Surg. 2018;44:87–95.
20. Ghaani S, Booms P, Ohrovska A, Kubersch A, Lorenz J, Rutzkowsk J, et al. Advanced platelet-rich fibrin: a new concept for cell-based tissue engineering by means of inflammatory cells. J Oral Implantol. 2014;40:679–89.
21. Fujioka-Kobayashi M, Miron RJ, Hernandez M, Kandalam U, Zhang Y, Choukroun J. Optimized Platelet- Rich Fibrin With The Low-Speed Concept: Growth Factor Release, Biocompatibility, and Cellular Response. J Periodontol. 2017;88:112–21.
22. Cho J-W, Kim S-A, Lee K-S. Platelet-rich plasma induces increased expression of G1 cell cycle regulators, type I collagen, and matrix metalloproteinase-1 in human skin fibroblasts. Int J Mol Med. 2012;29:232–6.
23. Perez AGM, Lana JFD, Rodrigues AA, Luzu ACM, Belangero WD, Santana MHA. Relevant aspects of centrifugation step in the preparation of platelet-rich plasma. ISRN Hematol. 2014;2014:176060.
24. Bielecki TM, Gazdk T, Arendt J, Szczepanski T, Köl W, Wielkożynski T, Antibacterial effect of autologous platelet gel enriched with growth factors and other active substances: an in vitro study. J Bone Joint Surg Br. 2007;89:417–20.
25. Schär MO, Diaz-Romero J, Kohl S, Zumstein MA, Nescic D. Platelet-rich concentrates differentially release growth factors and induce cell migration in vitro. Clin Orthop Relat Res. 2015;473:1635–43.
26. Sundman EA, Cole BJ, Fortier LA. Growth factor and catalytic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma. Ann J Sports Med. 2011;39:2133–40.

Ready to submit your research? Choose BMC and benefit from:
• fast, convenient online submission
• thorough peer review by experienced researchers in your field
• rapid publication on acceptance
• support for research data, including large and complex data types
• gold Open Access which fosters wider collaboration and increased citations
• maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions